NCT03482648View on ClinicalTrials.gov

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

October 3, 2018

Conditions
Ulcerative Colitis
Interventions
DRUG

BBT-401-1S, Single dose

Single dose of BBT-401-1S, 7 dose levels, oral capsule

DRUG

BBT-401-1S, Multiple doses

Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule

DRUG

Placebo

Placebo matched to BBT-401-1S, oral capsule

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Collaborators (1)

KCRN Research, LLC
All Listed Sponsors
collaborator

KCRN Research, LLC

INDUSTRY

lead

Bridge Biotherapeutics, Inc.

INDUSTRY

NCT03482648 - First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers | Biotech Hunter | Biotech Hunter